Emmaus Life Sciences (OTCMKTS:EMMA) Releases Quarterly Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) issued its quarterly earnings data on Friday. The company reported ($0.05) EPS for the quarter, Zacks reports.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS:EMMA remained flat at $0.01 during midday trading on Friday. The firm has a market cap of $808,308.04, a price-to-earnings ratio of -0.10 and a beta of 9.32. The firm has a 50-day moving average of $0.01 and a 200-day moving average of $0.01. Emmaus Life Sciences has a 1 year low of $0.01 and a 1 year high of $0.02.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.